NEULANDLAB
Neuland Laboratories Limited
If management delivers what it guided
arithmetic on filed guidance and past valuations · not a price target
NEULANDLAB
FY26 → FY27 · 1 year of guidance · ~0.7 years from today₹19,043 today
BEAR
₹6,909
-64%
11.6% a year · 21.8x exit
BASE
₹11,889
-38%
20% a year · 34.9x exit
BULL
₹18,806
-1%
27.2% a year · 52.1x exit
Where the market has priced it
14x67x today — outside the range57x
- the guided figure reached earnings through a low-confidence bridge
- the last 3 years priced this company 27% above its ten-year median (44x vs 35x) — the exit multiple here is the ten-year one, so a sustained re-rating would not be captured
- at 67x its FY26 earnings the stock already trades above the top of its own ten-year range (52x)
How these numbers are produced
| Earnings base | FY26 fiscal year EPS ₹283.71 (screener) |
|---|---|
| Guided growth | 20% a year, said on the call of 16-May-2026 · transcript |
| Read across as | operating: unlabelled growth figure, read as revenue — low confidence |
| Delivery calibration | 0.58x / 1x / 1.36x of what was guided — measured: 76 annual guided-vs-filed pairs + 77 near-complete quarterly years — NSE transcripts against the companies' own filings |
| Exit multiple | 21.83x / 34.92x / 52.12x, this company’s own p20 / median / p80 across 10 filed years |
| Filed-industry peers | median 28.43x across 38 peers — the cross-check, not the input |
| Arithmetic | base EPS × (1 + guided growth × delivery)1 × exit multiple |
Arithmetic on management’s own guidance and this company’s own past valuations. Not a price target, not a recommendation, and not a forecast of what the stock will do.
What management said
from NSE earnings-call filings · extracted, not interpreted
generic growth 20%
I think the 18% to 20% CAGR that we talked about is potential that we see.
Call 16-May-2026 · bridge confidence low · transcript PDF